These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 15254433)

  • 21. Abnormal MDMX degradation in tumor cells due to ARF deficiency.
    Li X; Gilkes D; Li B; Cheng Q; Pernazza D; Lawrence H; Lawrence N; Chen J
    Oncogene; 2012 Aug; 31(32):3721-32. PubMed ID: 22120712
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MDM2 but not MDM4 promotes retinoblastoma cell proliferation through p53-independent regulation of MYCN translation.
    Qi DL; Cobrinik D
    Oncogene; 2017 Mar; 36(13):1760-1769. PubMed ID: 27748758
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas.
    Toledo F; Wahl GM
    Nat Rev Cancer; 2006 Dec; 6(12):909-23. PubMed ID: 17128209
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Amplification of Mdmx and overexpression of MDM2 contribute to mammary carcinogenesis by substituting for p53 mutations.
    Yu Q; Li Y; Mu K; Li Z; Meng Q; Wu X; Wang Y; Li L
    Diagn Pathol; 2014 Mar; 9():71. PubMed ID: 24667108
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Benzimidazoles Downregulate Mdm2 and MdmX and Activate p53 in MdmX Overexpressing Tumor Cells.
    Mrkvová Z; Uldrijan S; Pombinho A; Bartůněk P; Slaninová I
    Molecules; 2019 Jun; 24(11):. PubMed ID: 31181622
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The MDM2 RING domain and central acidic domain play distinct roles in MDM2 protein homodimerization and MDM2-MDMX protein heterodimerization.
    Leslie PL; Ke H; Zhang Y
    J Biol Chem; 2015 May; 290(20):12941-50. PubMed ID: 25809483
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ensemble-based virtual screening reveals dual-inhibitors for the p53-MDM2/MDMX interactions.
    Barakat K; Mane J; Friesen D; Tuszynski J
    J Mol Graph Model; 2010 Feb; 28(6):555-68. PubMed ID: 20056466
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The MDMX acidic domain competes with the p53 transactivation domain for MDM2 N-terminal domain binding.
    Song Q; Liu XQ; Rainey JK
    Biochim Biophys Acta Mol Cell Res; 2022 Oct; 1869(10):119319. PubMed ID: 35780910
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The roles and regulation of MDM2 and MDMX: it is not just about p53.
    Klein AM; de Queiroz RM; Venkatesh D; Prives C
    Genes Dev; 2021 May; 35(9-10):575-601. PubMed ID: 33888565
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A site-directed mutagenesis study of the MdmX RING domain.
    Egorova O; Mis M; Sheng Y
    Biochem Biophys Res Commun; 2014 May; 447(4):696-701. PubMed ID: 24755078
    [TBL] [Abstract][Full Text] [Related]  

  • 31. On the interaction mechanisms of a p53 peptide and nutlin with the MDM2 and MDMX proteins: a Brownian dynamics study.
    ElSawy KM; Verma CS; Joseph TL; Lane DP; Twarock R; Caves LS
    Cell Cycle; 2013 Feb; 12(3):394-404. PubMed ID: 23324352
    [TBL] [Abstract][Full Text] [Related]  

  • 32. AXL receptor signalling suppresses p53 in melanoma through stabilization of the MDMX-MDM2 complex.
    de Polo A; Luo Z; Gerarduzzi C; Chen X; Little JB; Yuan ZM
    J Mol Cell Biol; 2017 Apr; 9(2):154-165. PubMed ID: 27927748
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Is MDMX the better target?
    Kon N; Gu W
    Aging (Albany NY); 2018 Jun; 10(6):1184-1185. PubMed ID: 29905531
    [No Abstract]   [Full Text] [Related]  

  • 34. In vitro and in silico studies of MDM2/MDMX isoforms predict Nutlin-3A sensitivity in well/de-differentiated liposarcomas.
    Bozzi F; Conca E; Laurini E; Posocco P; Lo Sardo A; Jocollè G; Sanfilippo R; Gronchi A; Perrone F; Tamborini E; Pelosi G; Pierotti MA; Maestro R; Pricl S; Pilotti S
    Lab Invest; 2013 Nov; 93(11):1232-40. PubMed ID: 24018792
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mdm2 requires Sprouty4 to regulate focal adhesion formation and metastasis independent of p53.
    de Queiroz RM; Efe G; Guzman A; Hashimoto N; Kawashima Y; Tanaka T; Rustgi AK; Prives C
    Nat Commun; 2024 Aug; 15(1):7132. PubMed ID: 39164253
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel simplified yeast-based assays of regulators of p53-MDMX interaction and p53 transcriptional activity.
    Leão M; Gomes S; Soares J; Bessa C; Maciel C; Ciribilli Y; Pereira C; Inga A; Saraiva L
    FEBS J; 2013 Dec; 280(24):6498-507. PubMed ID: 24119020
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular mechanism of CCDC106 regulating the p53-Mdm2/MdmX signaling axis.
    Zhou T; Ke Z; Ma Q; Xiang J; Gao M; Huang Y; Cheng X; Su Z
    Sci Rep; 2023 Dec; 13(1):21892. PubMed ID: 38081879
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MDMX Recruits UbcH5c to Facilitate MDM2 E3 Ligase Activity and Subsequent p53 Degradation
    Yang J; Jin A; Han J; Chen X; Zheng J; Zhang Y
    Cancer Res; 2021 Feb; 81(4):898-909. PubMed ID: 33277368
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interplay between MDM2, MDMX, Pirh2 and COP1: the negative regulators of p53.
    Wang L; He G; Zhang P; Wang X; Jiang M; Yu L
    Mol Biol Rep; 2011 Jan; 38(1):229-36. PubMed ID: 20333547
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Validation of MdmX as a therapeutic target for reactivating p53 in tumors.
    Garcia D; Warr MR; Martins CP; Brown Swigart L; Passegué E; Evan GI
    Genes Dev; 2011 Aug; 25(16):1746-57. PubMed ID: 21852537
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.